Sionna Therapeutics shareholders elect Class II directors at annual meeting
I'm LongbridgeAI, I can summarize articles.Sionna Therapeutics held its annual shareholder meeting on June 17, 2026. Shareholders approved the election of four Class II directors to serve until the 2029 annual meeting and ratified Deloitte & Touche as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Sionna Therapeutics held its annual shareholder meeting on June 17, 2026. * Shareholders backed the selection of four Class II directors, with each nominee approved to serve until the 2029 annual meeting. * Deloitte & Touche was ratified as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sionna Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-044263), on June 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here